How I treat newly diagnosed acute myeloid leukemia in an outpatient setting: a multidisciplinary team perspective
| Autor: | Katherine Tobon, Diedra K. Frantz, Chetasi Talati, Amber Lubas, Timothy Kubal, Christopher Salamanca |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
Chemotherapy medicine.medical_specialty business.industry Venetoclax medicine.medical_treatment Myeloid leukemia General Medicine Newly diagnosed Multidisciplinary team 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Quality of life (healthcare) Oncology chemistry 030220 oncology & carcinogenesis Health care medicine Outpatient setting business Intensive care medicine 030215 immunology |
| Zdroj: | Future Oncology. 16:281-291 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2019-0781 |
| Popis: | Historically, patients with acute myeloid leukemia received intensive chemotherapy requiring hospitalization, which can diminish quality of life and increase healthcare costs. The introduction of new therapies facilitated a shift toward outpatient therapy, which requires coordination of a multidisciplinary team, thorough patient evaluation, careful preparation and rigorous patient monitoring. Many patients are candidates for multiple treatment approaches; we generally employ CPX-351 (Vyxeos®) as an intensive outpatient approach and venetoclax (Venclyxto/Venclexta®) plus hypomethylating agents as a lower-intensity approach, with 2–3 visits/week during treatment. Treatment infusions are scheduled in the morning to leave sufficient time for transfusions and other supportive care later the same day, to prevent additional visits. With careful planning and patient monitoring, acute myeloid leukemia treatment can be successfully administered in the outpatient setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|